...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Phase 1b/2 trial expected to initiate 1Q 2019

Transfer was at $0.63 USF or $0.83 CDN +/-

Share
New Message
Please login to post a reply